ACC 23: TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial

Подробнее о видео

We are joined onsite by Dr John Forrest (Yale Valve Clinic, US) in this short video, who outlines the three-year outcomes of the Evolut Low-Risk Trial (Medtronic Cardiovascular). This study aimed to compare transcatheter aortic valve replacement (TAVR) using Medtronic's TAVR valve with surgical aortic valve replacement (SAVR) in over 2000 patients with aortic stenosis who had low surgical risk.

TAVR had consistent benefit at 3 years compared with surgery in terms of all-cause mortality and disabling stroke.

Questions:
-What is the reasoning behind this trial?
-Please outline the patient population and study design.
-What are the main results?
-What are the implications of these findings for clinical practice?
-What further research is required?

For more content from ACC.23/WCC and the Late-breaker Discussion series head to Late-Breaking Science Video Collection.

Recorded on-site at ACC.23, New Orleans, 2023.
Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter: